menu
    • menu
    [{"orgOrder":0,"company":"Avillion LLP","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Salbutamol Sulphate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Avillion LLP","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Aerosol for Inhalation","sponsorNew":"Avillion LLP \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Avillion LLP \/ AstraZeneca"},{"orgOrder":0,"company":"Avillion LLP","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"IL-17A\/IL-17F receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Avillion LLP","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Avillion LLP \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avillion LLP \/ Inapplicable"},{"orgOrder":0,"company":"Avillion LLP","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Sonelokimab","moa":"IL-17A\/IL-17F receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Avillion LLP","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Avillion LLP \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Avillion LLP \/ Merck & Co"}]

    Find Clinical Drug Pipeline Developments & Deals by Avillion LLP

    Menu

    Avillion LLP

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Avillion LLP

                            United Kingdom arrow
                            AACR Annual meeting
                            Not Confirmed

                            Avillion LLP

                            United Kingdom arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Salbutamol Sulphate,Budesonide

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase III

                            Sponsor : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            US FDA Accepts New Drug Application Filed by Avillion for Astra Zeneca's PT027 For the As-Needed Treatment or ...

                            Details : PT027 (Albuterol Sulfate) is a potential first-in-class inhaled, fixed-dose combination of albuterol, a short-acting beta2-agonist (SABA), and budesonide, an inhaled corticosteroid (ICS), in the US, being developed by Avillion and AstraZeneca under an ag...

                            Product Name : PT027

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 31, 2022

                            Lead Product(s) : Salbutamol Sulphate,Budesonide

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Sponsor : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Avillion LLP

                            United Kingdom arrow
                            AACR Annual meeting
                            Not Confirmed

                            Avillion LLP

                            United Kingdom arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sonelokimab

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Avillion's Positive Phase 2 Trial of Tri-Specific Nanobody® Sonelokimab (M1095) in Chronic Psoriasis Publishe...

                            Details : Sonelokimab is a novel tri-specific Nanobody® targeting IL 17A and IL-17F that also has an extended half-life and enhanced biodistribution through engineered binding affinity to albumin.

                            Product Name : M1095

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            April 23, 2021

                            Lead Product(s) : Sonelokimab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Avillion LLP

                            United Kingdom arrow
                            AACR Annual meeting
                            Not Confirmed

                            Avillion LLP

                            United Kingdom arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sonelokimab

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Results from Avillion's Phase 2 Trial of Sonelokinab in Chronic Psoriasis Presented in Late-Breaking News Sess...

                            Details : Sonelokinab is a novel investigational IL-17 A/F Nanobody® that neutralizes both IL-17A and IL-17F. The trial met its primary endpoint based on Investigator's Global Assessment at week 12 with clinically meaningful and statistically significant results ...

                            Product Name : M1095

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            October 29, 2020

                            Lead Product(s) : Sonelokimab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth